Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals, which is the company's sole segment. Inpatient rehabilitation contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. The company's inpatient rehabilitation hospitals provide a higher level of rehabilitative care to patients who are recovering from conditions such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.
Last trade$139.33
Day change-$2.78 (-1.96%)
Day range$139.15 – $142.23
Volume367,777
Market cap$13.94B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$13.94B
Price / earnings
21.69×
Price / book
5.2×
Price / sales
2.2×
EV / sales
2.6×
EV / EBITDA
10.22×
Profitability
Earnings per share
$6.55
Return on assets
8.5%
Return on equity
23.98%
Dividend yield
0.55%
Liquidity and leverage
Debt / equity
0.97×
Current ratio
1.09×
Quick ratio
1.09×
Cash ratio
0.08×
Cash flow
Price / cash flow
10.7×
Price / free cash flow
30.5×
Free cash flow
$457.2M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for EHC, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$1.61B
$1.6B
$1.59B
$1.54B
$1.48B
$1.46B
$1.46B
$1.41B
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$1.61B
$1.6B
$1.59B
$1.54B
$1.48B
$1.46B
$1.46B
$1.41B
Selling, general and administrative
$900.6M
$882.9M
$876.3M
$869.5M
$840.9M
$827.1M
$814.6M
$811.3M
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$1.32B
$1.31B
$1.29B
$1.26B
$1.23B
$1.2B
$1.19B
$1.17B
Operating income
$288M
$288.4M
$301.6M
$283.4M
$243.6M
$259.1M
$267M
$232.3M
Interest expense
-$32.2M
-$32.8M
-$31.8M
-$30.2M
-$30.8M
-$30.4M
-$31.8M
-$33M
Income before taxes
$257.8M
$261.6M
$288.7M
$257.7M
$219.9M
$236.8M
$238.6M
$201.4M
Income taxes
$53.4M
$53.6M
$56.4M
$55.4M
$44.9M
$51M
$41.6M
$37.6M
Net income
$203.6M
$207.4M
$248.2M
$203.1M
$174.6M
$184.9M
$196.5M
$164.2M
Net income attributable to common shareholders
$149.9M
$153.9M
$194.5M
$144.6M
$126.5M
$142.1M
$151.5M
$118.1M
EBITDA
$383.7M
$469.2M
$388.9M
$369.8M
$326M
$418.9M
$346.2M
$310.3M
Basic earnings per share
$1.52
$1.55
$1.96
$1.44
$1.26
$1.41
$1.50
$1.18
Diluted earnings per share
$1.50
$1.54
$1.93
$1.42
$1.24
$1.39
$1.48
$1.15
Recent news
Company coverage with links to the original publishers.
Encompass Health Corporation, a provider of integrated healthcare services with 173 hospitals across 39 states and Puerto Rico, has been identified as a momentum stock worth watching. The company holds a Zacks Rank #2 (Buy) rating with a VGM Score of A and Momentum Style Score of B. Six analysts revised earnings estimates upward in the last 60 days, with the consensus estimate increasing to $6.23 per share for fiscal 2026. Shares are up 12.4% over the past four weeks, and the company boasts an average earnings surprise of +8.5%.
BrightSpring Health Services (BTSG) shares jumped 11.3% following strong Q3 results with revenues up 26.4% to $4.21B and adjusted EPS surging 80%. The company raised its 2026 guidance, but its elevated 30.9X forward P/E valuation leaves limited room for execution errors. While specialty pharmacy growth and margin expansion support the rally, sustained earnings delivery and successful margin conversion remain critical for future gains.
Encompass Health (EHC) has earned a Zacks Momentum Style Score of A and a #2 (Buy) rating, driven by strong short-term price performance outpacing its industry peers and positive earnings estimate revisions. The stock has gained 9.52% over the past week and 19.37% over the past year, significantly outperforming the S&P 500.
The stock market closed with mixed results as technology stocks declined while healthcare, consumer staples, and financial sectors showed strength. Encompass Health (EHC) was highlighted as a stock to watch with a #2 Buy rating and strong Style Scores.
Encompass Health reported Q3 2026 revenue of $1.61 billion, up 8.9% year-over-year, beating consensus estimates by 0.63%. EPS came in at $1.52, exceeding the consensus estimate of $1.38 by 10.15%. Key metrics showed net patient revenue per discharge of $22,543 (above estimates) and inpatient revenues up 9.9% year-over-year, though discharges slightly missed expectations and other operating revenues declined 19.5%. The stock holds a Zacks Rank #3 (Hold) rating and has underperformed the broader market over the past month.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
Declared upcoming dividend$0.21 per share
Declared
Oct 22, 2026
Ex-dividend
Jan 4, 2027
Pay date
Jan 15, 2027
Ex-dividend
Amount / share
Pay date
Type
Oct 1, 2026
$0.21
Oct 15, 2026
recurring
Jul 1, 2026
$0.19
Jul 15, 2026
recurring
Apr 1, 2026
$0.19
Apr 15, 2026
recurring
Jan 2, 2026
$0.19
Jan 15, 2026
recurring
Oct 1, 2025
$0.19
Oct 15, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.